Skystar Bio-Pharmaceutical, a bio-pharmaceutical company in China, announced that its new GMP certified production facilities have been completed and is fully operational.

The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government. GMP certification is a new pharmaceutical manufacturing standard in which all pharmaceutical companies must be in compliance with to be able to sell their products in China.

The increased demand for Skystar's products has been partially due to many competing firms being forced out of the industry due to these new stringent regulations.

The new facilities cover an area of over 7.74 acres and are among the most efficient and technologically advanced Bio-Pharmaceutical facilities in China. With the completion of these facilities Skystar's production capacity has drastically increased, allowing the Company to be able to meet a significant portion of the overwhelming demand for its products. 

"The completion of our new facilities is a momentous milestone for us," commented Weibing Lu, Chief Executive Office of Skystar Bio-Pharmaceutical. "Understanding and predicting the impact of the new GMP regulations on pharmaceutical companies, we took the initiative and invested over $10 million in building these facilities and have been rewarded with immediate results as demand for our products has substantially increased and Skystar has become one of the leading producers of veterinary pharmaceutical products in China."

Source:佚名